Phathom Pharmaceuticals, Inc. Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports a corporate governance action effective September 22, 2020. Phathom Pharmaceuticals is a Delaware corporation whose common stock trades on the Nasdaq Global Select Market under the symbol PHAT.
Material Corporate Action
- The board of directors approved an amendment to the company’s amended and restated bylaws.
- The amendment adds Article XI, establishing the federal district courts of the United States as the exclusive forum for claims arising under the Securities Act of 1933, unless the company consents in writing to an alternative forum.
- Any person or entity acquiring an interest in the company’s securities is deemed to have notice of and consented to the forum-selection provision.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, guidance, or other operating and financial metrics.
Outlook, Risks, and Unusual Items
The bylaw amendment may affect the forum in which federal securities-law claims against the company are litigated. The filing does not discuss business outlook, contingencies, litigation matters, or other unusual items.
Exhibit and Filing Detail
- Exhibit 3.1: Amended and Restated Bylaws of Phathom Pharmaceuticals, Inc.
- The report states that the amendment was effective September 22, 2020; the filing was signed and dated September 25, 2020.
Investor Verification Points
- Review the complete text of new Article XI in Exhibit 3.1.
- Confirm the scope and enforceability of the federal forum-selection provision under applicable securities laws.
- Verify whether subsequent filings amend, replace, or otherwise address this bylaw provision.